Weaknesses of this study include our inability to measure the impact of Foxa1 KO on urothelial proliferation in real time, and the fact that we did not use an inducible system to reversibly control Upk2-HRAS* expression after the development of urothelial hyperplasia. The gene discussed is FOXA1; the disease is urothelial hyperplasia.